Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GD2 monoclonal antibody 3F8
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Anti-GD2 monoclonal antibody 3F8 is a murine IgG3 monoclonal antibody that targets the ganglioside GD2, which is highly expressed on neuroblastoma cells and has limited distribution in normal tissues. The drug acts primarily through immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It has been used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunotherapy for high-risk neuroblastoma, particularly for minimal residual disease or refractory cases. Clinical studies have demonstrated its efficacy against neuroblastoma, but the development of human antimouse antibodies can limit repeated dosing due to increased clearance and reduced efficacy. Humanized versions of this antibody have been developed to address immunogenicity concerns[1][5][7].
- Other names
- anti-GD2 monoclonal antibody 3F8anti-GD-2 monoclonal antibody 3F8anti-GD 2 monoclonal antibody 3F8m3F8m-3F8m 3F8
02
Targets
GD2
Beyond the preview
Go deeper on anti-GD2 monoclonal antibody 3F8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GD2 monoclonal antibody 3F8.